<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687947</url>
  </required_header>
  <id_info>
    <org_study_id>FHM-CGRP-MA-2008</org_study_id>
    <nct_id>NCT00687947</nct_id>
  </id_info>
  <brief_title>Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)</brief_title>
  <acronym>CGRP-2008</acronym>
  <official_title>CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EUROHEAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to explore the importance of migraine phenotype on the
      headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from
      spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous
      migraine attacks with an inhibitor of CGRP is effective in many patients. These data show
      that CGRP is involved in migraine pathophysiology.

      The importance of migraine genetics is disputed. Evidence from FHM patients with known
      mutations indicates that migraine pathways in FHM may be different from normal migraine. The
      aim of the present study is to examine whether this difference also exists in FHM patients
      without known mutations. The project will improve our understanding of the neurobiology of
      migraine and stimulate development of new treatment targets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine and associated symptoms</measure>
    <time_frame>0-14 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Migraine aura</measure>
    <time_frame>0 - 14 h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Familial Hemiplegic Migraine</condition>
  <condition>Migraine With Aura</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MA-patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FHM-patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGRP</intervention_name>
    <description>CGRP (0.5 ug/min) infused intravenously over 20 min</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of familial hemiplegic migraine (IHS-classification criteria)

          -  Diagnosis of migraine with aura(IHS-classification criteria)

          -  Healthy controls

        Exclusion Criteria:

        Patients and controls:

          -  A history of cerebrovascular disease and other CNS- disease

          -  A history of serious somatic and mental disease

          -  A history suggesting ischaemic heart disease

          -  A history of hypo- or hypertension

          -  Daily intake of medication apart from oral contraceptives

          -  Abuse of alcohol or medicine (opioid analgesics).

          -  Pregnant or breastfeeding women.

          -  On the study day:

               -  No intake of a simple analgesic in the previous 48 hours

               -  No headache in the previous 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Møller Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital</name>
      <address>
        <city>Glostrup, Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.glostruphospital.dk/danishheadachecenter/menu</url>
    <description>The homepage of the Danish headache center, Glostrup, Copenhagen, Denmark</description>
  </link>
  <reference>
    <citation>Hansen JM, Thomsen LL, Olesen J, Ashina M. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia. 2008 May;28(5):496-505. doi: 10.1111/j.1468-2982.2008.01559.x. Epub 2008 Mar 31.</citation>
    <PMID>18384418</PMID>
  </reference>
  <reference>
    <citation>Hansen JM, Thomsen LL, Marconi R, Casari G, Olesen J, Ashina M. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia. 2008 Apr;28(4):367-75. doi: 10.1111/j.1468-2982.2008.01542.x. Epub 2008 Feb 22.</citation>
    <PMID>18294248</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>July 31, 2009</last_update_submitted>
  <last_update_submitted_qc>July 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jakob Møller Hansen, MD</name_title>
    <organization>Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital</organization>
  </responsible_party>
  <keyword>FHM</keyword>
  <keyword>MA</keyword>
  <keyword>healthy controls</keyword>
  <keyword>CGRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

